Efficacy and safety of tegoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials.

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of 14-day tegoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy (BQT) for first-line Helicobacter pylori eradication in 1541 treatment-naïve participants. The analysis found no significant difference in eradication efficacy between the two therapies (risk ratio, 0.996; P = 0.93), suggesting dual therapy may be a viable alternative.

Key findings

• 14-day tegoprazan-amoxicillin dual therapy showed no significant difference in eradication efficacy compared to BQT (risk ratio, 0.996; P = 0.93).
• Sensitivity analysis with proton pump inhibitor-based BQT also showed no significant difference (risk ratio, 0.985; P = 0.80).
• Adverse events and treatment discontinuation were generally more frequent in BQT arms than in dual-therapy arms.

Why it matters

The findings indicate that tegoprazan-amoxicillin dual therapy may provide a simpler and potentially better-tolerated option for H. pylori eradication, which could enhance patient adherence and treatment outcomes.